TET2 and lung carcinoma: The expression level of TET2 is decreased in liver cancer, breast cancer, lung cancer, prostate cancer and other solid tumor tissues compared to normal tissues, and this downregulation decreases the content of its catalytic product 5-hmC, which is closely related to tumor development (10, 11).